PO:17:252 | The choice between belimumab and anifrolumab: analysis of a monocentric cohort
Background. Belimumab (BEL) and Anifrolumab (ANI) are currently the only biologic drugs authorized for the treatment of Systemic Lupus Erythematosus (SLE). The aim of the study is to analyze the factors associated with the therapeutic choice between BEL and ANI in a monocentric cohort of patients a...
Gardado en:
| Autor Principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
PAGEPress Publications
2025-11-01
|
| Series: | Reumatismo |
| Assuntos: | |
| Acceso en liña: | https://www.reumatismo.org/reuma/article/view/2167 |
| Tags: |
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|